Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694913 · ClinicalTrials.gov registry record
Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 82
- Enrollment target
NCT02694913 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 82 participants.
The verdict
NCT02694913 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
This is a non-interventional, R01-funded pilot study that will identify serum and cellular markers in patients' blood samples that can be used as short-term biomarkers of rituximab response. We hypothesize that serum complement levels, activation of natural killer cells, and clearance of peripheral B-cells will be accurate biomarkers of rituximab response, and may be correlated with long-term outcomes.
Interventions
- OTHER Non Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-02-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02694913
The ClinicalTrials.gov registry entry for NCT02694913 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non Interventional is the first listed.
NCT02694913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02694913 about?
NCT02694913 is a clinical study titled "Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies". This is a non-interventional, R01-funded pilot study that will identify serum and cellular markers in patients' blood samples that can be used as short-term biomarkers of rituximab response. We hypothesize that serum complement levels, activation of natural killer cells, and clearance of peripheral ...
What is the current status of trial NCT02694913?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2015-11. Estimated completion is 2019-02-07.
What interventions are being tested in trial NCT02694913?
The interventions under investigation include: Non Interventional (OTHER).
Who is sponsoring clinical trial NCT02694913?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.